

17. SEP. 2003 10:12

BUREAU DES BREVETS

Nº1048 P. 3



RECEIVED
SEP 26 2003

PATENT

Customer No. 22,832
Attorney Docket No. 2000000073-01
~~REC'D 26 SEP 2003~~
~~1000/1300/2900~~

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Sebastian SUERBAUM et al.) Group Art Unit: 1647
Serial No.: 09/015,078) Examiner: Sharon L. TURNER
Filed: January 29, 1998)
For: CLONING AND CHARACTERIZATION)
OF THE FibA GENE OF *H. PYLORI*,)
PRODUCTION OF AFFLAGELLATE)
STRAINS)

Commissioner for Patents and Trademarks
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

DECLARATION UNDER 37 C.F.R. § 1.132

I, Agnès Labigne, do hereby declare and say:

1. I am one of the joint inventors of the subject matter disclosed in U.S. patent application Serial No. 09/015,078.
2. Attached hereto as Exhibit A are claims 66-87.
3. On information and belief, claims 66-87 of Exhibit A are pending in U.S. patent application Serial No. 09/015,078.
4. I have examined claims 66-87 of Exhibit A and I believe that I am a joint inventor of the subject matter of these claims.
5. I am coauthor of an Abstract identified as Suerbaum et al., "Cloning, Sequencing, and Mutagenesis of the *H. pylori* fibA Gene - a Homolog of the

FINNEGAN
ENDERSON
ARABOW
ARRETT &
UNNER LLP

500 I Street, NW
Washington, DC 20005
202.408.4000
x 202.408.4400
www.finnegan.com

Application Serial No.: 09/015,078
Attorney Docket No.: 02356.0073-01

lcrD/fibF/invA Family of Genes Associated with Motility and Virulence," a copy of which is attached hereto as Exhibit B.

6. I am also coauthor of an Abstract identified as Suerbaum et al., "Cloning, Expression, and Mutagenesis of the *H. pylori fibA* Gene - a Homolog of the *lcrD/fibF* Family of Genes Associated with Motility and Virulence," a copy of which is attached hereto as Exhibit C.

7. Collectively, these abstracts will hereinafter be referred to as the "Suerbaum Abstracts."

8. I am a joint inventor on the Suerbaum Abstracts.

9. On information and belief, the Suerbaum Abstracts have been cited against claims 66-78 in the U.S. patent application Serial No. 09/015,078 because A. Schmitz and C. Josenhans are named as coauthors of the Suerbaum Abstracts, but are not named as coinventors in U.S. patent application Serial No. 09/015,078, and based on these circumstances, the U.S. Patent Examiner asserted that the subject matter disclosed in U.S. patent application Serial No. 09/015,078, and the subject matter claimed in claims 66-87 in Exhibit A, were not invented by the inventors named in the application.

9. The experimental work described in the Suerbaum Abstracts was conducted by Sebastian Suerbaum, or Agnès Labigne, or performed under our direction or supervision.

10. A. Schmitz and C. Josenhans worked under our supervision. Under our instructions, A. Schmitz rendered technical analysis in sequence analysis and C. Josenhans rendered technical assistance with immunoblot experiments. A. Schmitz

FINNEGAN
ENDERSON
ARABOW
CARRETT &
UNNER LLP

901 Street, NW
Washington, DC 20005
202.408.4000
x 202.408.4400
www.finnegan.com

Application Serial No.: 09/015,078
Attorney Docket No.: 02356.0073-01


and C. Josenhans were rewarded for their work by being included as coauthors of the Suerbaum Abstracts.

11. A. Schmitz and C. Josenhans did not make an inventive contribution to the experimental work described in the Suerbaum Abstracts, or an inventive contribution to the subject matter disclosed in U.S. patent application Serial No. 09/015,078, or an inventive contribution to the subject matter of claims 66-87 of Exhibit A, and A. Schmitz and C. Josenhans are not joint inventors of this subject matter.

12. The undersigned declares further that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing therefrom.

Signed at Paris, France

By:


Agnès Labigne

Dated: September 16, 2003

FINNEGAN
ENDERSON
ARABOW
ARRETT &
UNNER LLP

601 Street, NW
ington, DC 20005
202.408.4000
x 202.408.4400
www.finnegan.com

U.S. Patent Application No. 09/015,078

Filed: January 1, 1998

Title: CLONING AND CHARACTERIZATION OF THE *flbA* GENE
OF *H. PYLORI* PRODUCTION OF AFLAGELLATE STRAINS

Based on FR 9508068 filed July 4, 1995

Inventors: Sebastian SUERBAUM et al.

Your Reference: DI No. 95-22

Our Reference: 02356.0073-01

66. An *H. pylori* bacterial strain, or an extract of an *H. pylori* bacterial strain, wherein the *H. pylori* bacterial strain has an aflagellate phenotype resulting from a mutation in the *flbA* gene of the *H. pylori* bacterial strain.

67. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 66, wherein the *flbA* gene is able to hybridize, under conditions of stringency, with a probe corresponding to a nucleotide fragment from *H. pylori*, which has been amplified using two oligonucleotides having the following sequences:

OLF1bA-1: ATGCCTCGAGGTCGAAAAGCAAGATG (SEQ ID NO:1),

OLF1bA-2: GAAATCTTCATACTGGCAGCTCCAGTC (SEQ ID NO:2).

68. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 66, wherein the *flbA* gene comprises SEQ ID NO: 6.

69. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 66, wherein the *H. pylori* bacterial strain does not express the hook protein (or anchoring protein) of the flagellum of *H. pylori*.

70. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 66, wherein the *H. pylori* bacterial strain also lacks the flagellum sheath.

71. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 70, wherein the *H. pylori* bacterial strain does not express the hook protein (or anchoring protein) of the flagellum of *H. pylori*.

72. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 66, wherein the *H. pylori* bacterial strain is obtained from strain N6 having deposit Accession No. NCIMB 40512.

73. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 66, wherein the *H. pylori* bacterial strain is strain N6fibA⁻ having deposit Accession No. NCIMB 40747.

74. The extract of an *H. pylori* bacterial strain according to claim 66, wherein the bacterial extract is a total bacterial extract.

75. The extract of an *H. pylori* bacterial strain according to claim 66, wherein the bacterial extract is a n-octyl glucoside extract.

76. The extract of an *H. pylori* bacterial strain according to claim 66, wherein the bacterial extract is obtained after extracting with PBS or glycine.

77. An *H. pylori* bacterial strain, or an extract of an *H. pylori* bacterial strain, wherein the *H. pylori* bacterial strain has an aflagellate phenotype resulting from a mutation in the *fibA* gene of the *H. pylori* bacterial strain, and wherein the *H. pylori* bacterial strain does not express the FlaA and FlaB proteins.

78. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 77, wherein the *fibA* gene is able to hybridize, under conditions of stringency, with a probe corresponding to a nucleotide fragment from *H. pylori*, which has been amplified using two oligonucleotides having the following sequences:

OLF1bA-1: ATGCCCTCGAGGTCGAAAGCAAGATG (SEQ ID NO:1),

OLF1bA-2: GAAATCTTCATACTGGCAGCTCCAGTC (SEQ ID NO:2).

79. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 77, wherein the *flbA* gene comprises SEQ ID NO: 6.
80. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 77, wherein the *H. pylori* bacterial strain does not express the hook protein (or anchoring protein) of the flagellum of *H. pylori*.
81. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 77, wherein the *H. pylori* bacterial strain also lacks the flagellum sheath.
82. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 81, wherein the *H. pylori* bacterial strain does not express the hook protein (or anchoring protein) of the flagellum of *H. pylori*.
83. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 77, wherein the *H. pylori* bacterial strain is obtained from strain N6 having deposit Accession No. NCIMB 40512.
84. The *H. pylori* bacterial strain, or extract of an *H. pylori* bacterial strain, according to claim 77, wherein the *H. pylori* bacterial strain is strain N6^{flbA-} having deposit Accession No. NCIMB 40747.
85. The extract of an *H. pylori* bacterial strain according to claim 77, wherein the bacterial extract is a total bacterial extract.
86. The extract of an *H. pylori* bacterial strain according to claim 77, wherein the bacterial extract is a n-octyl glucoside extract.
87. The extract of an *H. pylori* bacterial strain according to claim 77, wherein the bacterial extract is obtained after extracting with PBS or glycine.

of
ic ulcer
antham ETB.
ieñora de
id antigens.
ic ulcer and
nt reports,
and sialic
We examined
gastric
lated it to
ptic ulcers
ferred for
o difference
infection or
different
use-
id higher
(O.R. 3.18, p
sis (a-b-)
i to patients
dition of
testinal-
o different
conditions. In
serves as a
the prevalence
different
sontype and H.
ic carcinoma
s interact in

Cloning, Sequencing, and Mutagenesis of the *H. pylori* *fba* Gene - a Homolog of the *lcrD/fibF/invA* Family of Genes Associated with Motility and Virulence.

S. Suerbaum, A. Schmitz, C. Josenhans, A. Labigne

Med. Microbiol., Ruhr-University Bochum (Germany), and Unité des Entérobactéries, INSERM U389, Institut Pasteur, Paris (France).

The HP flagellar filament contains two functionally different flagellin molecules, FlaA and FlaB. The genes encoding these flagellins have been cloned and characterized. The ability of the bacterium to regulate the amounts of FlaA and FlaB in the filament is believed to play a role in the adaptation of the filament to environmental conditions (viscosity), however, little is known about motility regulation in HP. Recently, a family of conserved proteins involved in the regulation and/or secretion of virulence-associated proteins has been described. Two members of this family, *Caulobacter crescentus* FlbF and *Campylobacter jejuni* FlbA are required for flagellar biosynthesis and considered regulators of motility intervening at the beginning of the regulatory cascade of motility proteins. We have cloned the gene coding for the LcrD/FibF homolog of HP. A fragment of the gene was amplified from the HP chromosome using degenerate primers based on highly conserved regions of the proteins and then used to screen a HP cosmid gene bank. After subcloning, the gene (2.1 kb, designated *fba*) was sequenced. The predicted FlbA gene product had a predicted molecular weight of 79 kDa and exhibited high degrees of homology with the other known members of the LcrD/FibF protein family. The open reading frame was preceded by a putative sigma 28 consensus promoter sequence. Isogenic mutants of *H. pylori* in the *fba* gene were constructed by disruption with a kanamycin resistance cassette and electroporation-mediated allelic exchange. The *fba* mutants were characterized by SDS-PAGE, Western blotting, motility testing and electron microscopy. FlbA mutants were completely devoid of flagella and did not express FlaA or FlaB protein. In concordance with these data, *fba* mutants were completely non-motile. In addition, *fba* mutants lacked several other protein bands that may represent yet unknown virulence-associated or flagellar proteins and that are presently being characterized.

SPECIFIC THERAPY WITH HELICO-
Olene Samo-
v. Medical

the level
Helicobacter
was studied.
united: 51 men
an duration
is has been

EXTRACT OF *HELICOBACTER PYLORI* INDUCES GASTRIC MICRO CIRCULATORY DAMAGE IN RATS -ROLE OF ACTIVATED NEUTROPHILS-

M.Suzuki, M.Mori, S.Miura, and H.Ishii

Dept. of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan


H.pylori-derived chemotaxin has been proposed as one of virulent factors in gastritis and gastric ulcer. In this paper, the influence of water extract of *H.pylori* in rat mesenteric and gastric microcirculation was investigated by using intravital microscopy.

ABSTRACTS

95th GENERAL MEETING

WASHINGTON
CONVENTION CENTER

WASHINGTON, DC
21-25 MAY 1995



Univ. of Minn.

Bio-Medical

Library

12 14 95

ISSN 0067-2777

- B-89** The Role of Chemotaxis in Invasion of *Campylobacter jejuni* into Eukaryotic Cells. RUIJIN YAO¹, DON H. BURR AND PATRICIA GUERRY. Enteric Diseases Program, Naval Medical Research Institute, Bethesda, MD and the FDA, Washington, D. C.

Motility has been shown to be an important virulence determinant for *Campylobacter* spp. Non-flagellated and flagellated but non-motile (paralyzed) organisms are unable to colonize *in vivo* or to invade epithelial cells *in vitro*. In order to determine if chemotaxis or motility itself is necessary, we have examined the role of the *cheY* gene of *C. jejuni* in *in vitro* invasion. The *cheY* gene of *C. jejuni* 81-176 was cloned and sequenced and shown to encode a predicted protein of 119 amino acids with a predicted M_r of 13,191. The predicted protein shares 40% identity and 67% similarity with the *CheY* protein of *Salmonella typhimurium*. The mutant was isolated by insertion of a kanamycin resistance cassette within the ORF, and re-introduction of the mutated allele into 81-176 by natural transformation. The resulting mutant was motile when examined by wet mount, but non-chemotactic on motility agar and in chemotactic assays. In *in vitro* invasion assays using INT407 cells, the *cheY* mutant invaded as well or slightly better than the parental strain, indicating that loss of chemotaxis does not significantly alter the invasiveness of *C. jejuni* in this assay. The role of chemotaxis *in vivo* is under investigation.

- B-90** *cagII*, a New Multigene Locus Only Present in the Most Virulent *Helicobacter pylori* Strains. N. S. AKOPYANTS, D. KERSULYTE and D. E. BERG¹. Dept. Molec Microbiol, Washington Univ. Med Sch., St. Louis, MO 63110. *Helicobacter pylori* strains that lead to peptic ulcers and gastric cancer produce a vacuolating cytotoxin (*vacA*) and an immunodominant cytotoxin-associated protein (*cagA*), whereas many strains from asymptomatic carriers do not produce either protein. We searched for new genes associated with *H. pylori* virulence using our ordered library of *H. pylori* cosmid clones (I) by hybridizing restriction digests of each cosmid with DNA from several *cagA*- (non-vir) and control *cagA*+ (vir) strains. A ~20 kb segment termed "*cagII*" was found in *cagA*+ strains, but was absent from *cagA*- strains. This *cagII* segment was cloned and, in turn, used as a hybridization probe. It hybridized with DNAs from each of 73 *cagA*+ strains, but not with DNAs from 32 of 33 *cagA*- strains. The *cagII* segment is hundreds of kb from *cagA* and from *vacA*. Assuming interstrain recombination during mixed infection (see 2) akin to that seen in the laboratory, we propose that the epidemiologic association between *cagII*, *cagA* and *vacA* is due to selection for functions they encode, not to chromosomal linkage. The ends of the *cagII* segment are being sequenced to gain insights into how *cagII* is acquired or lost during evolution. In addition, we are sequencing the entire 22 kb *cagII* region (collaboration with S. Clifton and B. Roe), in the expectation that some *cagII* encoded proteins will affect host interactions during *H. pylori* infection -- e.g., mucosal immune response, or events of tissue damage or cell proliferation.
- REFERENCES 1. Bukanov & Berg. Molec. Micro. 11:509-523, 1994.
2. Akopyants, Eaton & Berg. Inf. Immun. in press (Jan. 1995).

- B-91** Colonization of Granulocytic Piglets by *H. pylori* Deficient in Two Flagellin Genes. K. EATON¹, S. SUERBAUM¹, C. JOSENHANS², S. KRAKOWKA³; Ohio State University, Columbus, OH USA and Ruhr-Universität Bochum, Bochum, Germany. *H. pylori* possesses two flagellin molecules, FlaA, the major species, and FlaB, which is expressed in minor amounts, at least *in vitro*. Isogenic mutants of *H. pylori*, strain N8, were constructed by disruption of the *flaA* or *flaB* genes with a kanamycin (km) resistance cassette, or by introduction of both km and a chloramphenicol resistance gene (cat) to produce a double mutant. This study sought to determine if one or both flagellin species are necessary for colonization or persistence by *H. pylori*. Eighteen photobleachable piglets were given one of 4 isogenic strains of *H. pylori* orally, and killed 2 or 4 days post-inoculation (PI). Strain N8, the wild-type, produced both FlaA and FlaB and was fully motile in 0.5% agar. N8ΔflaBm expressed FlaB, but not FlaA, produced short, truncated flagella, and was weakly motile. N8ΔflaAm produced FlaA, but not FlaB, had apparently normal flagella, and was moderately motile, and N8ΔflaAΔflaBm did not produce any flagella and was non-motile.

Wild-type strain N8 colonized all piglets at both time intervals (mean club gastric mucus=1.9±1.0%). Both N8ΔflaAm and N8ΔflaBm also colonized at both time points, but colonization was weak (50-500cfu/g). In addition, in contrast to urease-negative mutants which fail to persist *in vivo*, colonization by both flagellin-negative mutants increased approximately one order of magnitude between 2 and 4 days PI. The double mutant, N8ΔflaAΔflaBm, also colonized for two days PI, but not 4 days PI.

These findings demonstrate that both flagellin species are necessary for full colonization by *H. pylori*, in spite of the fact that FlaB apparently has a minor role in motility *in vitro*. Weak colonization and persistence is possible in the absence of either flagellin species, but not both. Future studies will determine the duration of persistence of flagellin-negative strains.

- B-92** Characterization of a Cell Proliferation Inhibiting Factor (PIF) Produced by *Helicobacter pylori*. U. KNIPP¹, W. KAUP, S. BIRKHOLZ, and W. OPELKUCH. Ruhr-Univ. Bochum, Bochum, FRG.

Previous examinations by our group on *Helicobacter pylori* (HP), the causative agent of chronic type B gastritis in man, showed that a cytoplasmic fraction (CF) of HP suppresses the *in vitro* proliferative response of human mononuclear cells to mitogens and antigens. The present study demonstrates that the antiproliferative activity of CF also affects the spontaneous proliferation of different mammalian cell lines including U937, Jurkat and Kato3. This effect was obvious in the first 16 hours of incubation and maximal between 24 to 48 hours. In addition CF significantly diminished the protein synthesis of the cells in the first 6 hours of incubation comparable to cycloheximide and diphtheria toxin. The urease and the vacuolating cytotoxin of HP could be excluded as the causative agents for the antiproliferative effect using an isogenic urease negative mutant strain and cytotoxin negative strains. So far the inhibitory effects were not due to lytic or other lethal activities of CF. A preliminary physico-chemical characterization showed that the proliferation inhibiting factor (PIF) was non-dialyzable, heat-labile (70°C, 30 min), sensitive to proteases and had an apparent native molecular weight of 100±10 kDa. These results implicate the presence of a protein factor in HP with antiproliferative activity for immunocompetent and epithelial mammalian cells. It is reasonable to presume that this property may contribute to the pathogenesis of HP induced diseases.

- B-93** Cloning, Expression, and Mutagenesis of the *H. pylori* *fliD* Gene - a Homolog of the *LeuD/FliD* Family of Genes Associated with Motility and Virulence. S. SUERBAUM¹, A. SCHMITZ², C. JOSENHANS¹, A. LABIGNE².
- ¹Med. Microbiol. & Immunol., Ruhr-University, Bochum (Germany), and ²Unité de Gastroentérologie, INSERM U369, Institut Pasteur, Paris (France)
- Motility is an important virulence factor of *Helicobacter pylori* (HP). The genes encoding the flagellar proteins FliA and FliB have been cloned, but little is known about the regulation of flagellar biogenesis in this organism. Recently, a family of conserved proteins involved in the regulation and/or secretion of virulence-associated proteins has been described. Several members of this family are required for flagellar biogenesis and considered regulators of motility intervening at the beginning of the regulatory cascade of motility proteins. We have cloned the gene coding for the LeuD/FliD homolog of HP. The gene was amplified from the HP chromosome using degenerate primers and then used to screen a HP cosmid gene bank. After subcloning, the gene (2.2 kb, designated *fliD*) was sequenced. The predicted FliD gene product had a molecular mass of 80.1 kDa and exhibited high degree of homology with the other known members of the LeuD/FliD protein family. The *fliD* gene was PCR-cloned into the *E. coli* expression vector pQE30. Purification studies with the recombinant protein provided evidence that the protein has strong affinity for membranes, consistent with the strong hydrophobicity of the N-terminal part of FliD. Isogenic mutants of HP in the *fliD* gene were constructed by disruption with a kanamycin resistance cassette. The *fliD* mutants were characterized by Western blotting, motility testing, and electron microscopy. FliD mutants were completely devoid of flagella and flagellar sheath and did not express FliA or FliB protein. In accordance with these data, *fliD* mutants were completely non-motile. In addition, *fliD* mutants lacked several other protein bands that may represent yet unknown virulence-associated or flagellar proteins.

- B-94** *In Vitro* Translocation of *Helicobacter pylori* through Epithelial Cells. LUGONES-MARTINEZ V., and RUIZ-PALACIOS GM. Inst. Inst. Nutr. Mexico.

Adherence of *Helicobacter pylori* to epithelial cells is needed to establish the interaction between bacteria and the gastric mucosa, although other features, such as hydrophobicity and production of urease and cytotoxin (CTX), may play a role in this process. To study the bacteria-mucosa interaction by adherence and transcytosis through polarized cells, 3 prototype strains from different clinical presentations were studied. Sources of strains were: 1 CTX from chronic gastritis (Mexico); and 2 CTX from duodenal ulcer (USA and U.K.). Adherence was studied by the HBp-2 cell assay; transcytosis was assessed by counting the number of viable bacteria able to pass through a monolayer of polarized Caco-2 cells; and the monolayer integrity by measuring transepithelial resistance and by electron microscopy.

All strains were cell-adherent. Two adherence patterns were identified by the HBp-2 cell assay: diffuse (2str.) and aggregative (1 str.). The most significant finding was that *H. pylori* strains were able to translocate within 8 h across polarized Caco-2 cells without disrupting the monolayer. There was no correlation between clinical presentation of *H. pylori* infection and cell adherence or transcytosis across the polarized cell monolayer. The ability of *H. pylori* to translocate without damaging the epithelial cells seems to be an inherent property of the bacteria, and may be an important step towards reaching the lamina propria and induce an inflammatory response.